Anna S Berghoff1, Cornelia Sax1, Martin Klein2, Julia Furtner3, Karin Dieckmann4, Brigitte Gatterbauer5, Georg Widhalm5, Margaretha Rudas6, Christoph C Zielinski1, Rupert Bartsch1, Matthias Preusser1. 1. Department of Medicine I, Medical University of Vienna, Austria ; Comprehensive Cancer Center, CNS Tumors Unit (CCC-CNS), Medical University of Vienna, Vienna, Austria. 2. Department of Medical Psychology, VU University Medical Center, Amsterdam, The Netherlands. 3. Department of Neuroradiology, CNS Tumors Unit (CCC-CNS), Medical University of Vienna, Vienna, Austria ; Comprehensive Cancer Center, CNS Tumors Unit (CCC-CNS), Medical University of Vienna, Vienna, Austria. 4. Department of Radiotherapy, CNS Tumors Unit (CCC-CNS), Medical University of Vienna, Vienna, Austria ; Comprehensive Cancer Center, CNS Tumors Unit (CCC-CNS), Medical University of Vienna, Vienna, Austria. 5. Department of Neurosurgery, CNS Tumors Unit (CCC-CNS), Medical University of Vienna, Vienna, Austria ; Comprehensive Cancer Center, CNS Tumors Unit (CCC-CNS), Medical University of Vienna, Vienna, Austria. 6. Department of Pathology, CNS Tumors Unit (CCC-CNS), Medical University of Vienna, Vienna, Austria.
Abstract
BACKGROUND: Brain metastases (BM) are an increasing challenge in modern oncology, as treatment options especially after exhaustion of local treatment approaches are very limited. PATIENT AND METHODS: A long-term surviving patient with brain-only metastatic breast cancer, who presented at our department with massive corticosteroid-refractory brain edema with serious neurological symptoms after exhaustion of all local therapy options, was started on bevacizumab. RESULTS: Initiation of bevacizumab monotherapy led to rapid decrease of contrast-enhancing lesions and alleviation of brain edema, and allowed tapering and termination of corticosteroid administration. Neurological and neurocognitive function was restored and marked improvement in quality of life was observed. CONCLUSION: Our case highlights that bevacizumab may represent a feasible and effective salvage treatment option in selected patients with BM.
BACKGROUND: Brain metastases (BM) are an increasing challenge in modern oncology, as treatment options especially after exhaustion of local treatment approaches are very limited. PATIENT AND METHODS: A long-term surviving patient with brain-only metastatic breast cancer, who presented at our department with massive corticosteroid-refractory brain edema with serious neurological symptoms after exhaustion of all local therapy options, was started on bevacizumab. RESULTS: Initiation of bevacizumab monotherapy led to rapid decrease of contrast-enhancing lesions and alleviation of brain edema, and allowed tapering and termination of corticosteroid administration. Neurological and neurocognitive function was restored and marked improvement in quality of life was observed. CONCLUSION: Our case highlights that bevacizumab may represent a feasible and effective salvage treatment option in selected patients with BM.
Entities:
Keywords:
Bevacizumab; Brain edema; Brain metastases; Breast cancer; Neurocognitive functioning; Symptom control
Authors: Paul W Sperduto; Norbert Kased; David Roberge; Zhiyuan Xu; Ryan Shanley; Xianghua Luo; Penny K Sneed; Samuel T Chao; Robert J Weil; John Suh; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler Journal: J Clin Oncol Date: 2004-01-01 Impact factor: 44.544
Authors: Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: A Berghoff; Z Bago-Horvath; C De Vries; P Dubsky; U Pluschnig; M Rudas; A Rottenfusser; M Knauer; H Eiter; F Fitzal; K Dieckmann; R M Mader; M Gnant; C C Zielinski; G G Steger; M Preusser; R Bartsch Journal: Br J Cancer Date: 2012-01-10 Impact factor: 7.640
Authors: Emilie Le Rhun; Sophie Taillibert; Thomas Boulanger; Fahed Zairi; Jacques Bonneterre; Marc C Chamberlain Journal: Case Rep Oncol Date: 2015-02-12
Authors: Anna Sophie Berghoff; Michael Oliver Breckwoldt; Lars Riedemann; Kianush Karimian-Jazi; Sarah Loew; Franziska Schlieter; Julia Furtner; Marc Cinci; Michael Thomas; Moritz J Strowitzki; Frederik Marmé; Laura L Michel; Thomas Schmidt; Dirk Jäger; Martin Bendszus; Matthias Preusser; Wolfgang Wick; Frank Winkler Journal: Neurooncol Adv Date: 2020-03-16
Authors: Bogdana Kovalchuk; Anna S Berghoff; Matthia A Karreman; Katharina Frey; Manuel Piechutta; Manuel Fischer; Julia Grosch; Sabine Heiland; Michael O Breckwoldt; Frank Hilberg; Wolfgang Wick; Frank Winkler Journal: Clin Exp Metastasis Date: 2020-09-12 Impact factor: 5.150